Action Purple Biotech - PPBT

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

2,81

Prix Achat

2,10

Prix Vente

6,50

Volume échangé

3 911

2,7701 Fourchette du Jour 2,89

0,00 Plage de 52 semaines 0,00

Cap du marché

3,973M

Clôture Veille

2,94

Ouverture

2,7701

Dernière Transaction

2.85

Dernière heure de transaction

Volume financier

US$ 11 012

VWAP

2,8155

Volume moyen (3 m)

Actions en circulation

1 413 797

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

Chiffre d'affairess

Bénéfice net

-19,88M

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24. Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.

Secteur

Pharmaceutical Preparations

Industrie

Arrange Trans-freight, Cargo

Site Web

www.purple-biotech.com

Siège social

Rehovot, Center, Isr

Fondé

2013

Purple Biotech Ltd est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker PPBT. Le dernier cours de clôture d'Purple Biotech était de US$2,94. Au cours de la dernière année, les actions de Purple Biotech ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Purple Biotech compte actuellement 1 413 797 actions en circulation. La capitalisation boursière d'Purple Biotech est de US$4,16 million.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

NT219 in combination with EGFR antibody cetuximab (Erbitux) is currently entering a Phase 2 study for head and...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

PPBT - Frequently Asked Questions (FAQ)

What is the current Purple Biotech share price?

The current share price of Purple Biotech is US$ 2,81

How many Purple Biotech shares are in issue?

Purple Biotech has 1 413 797 shares in issue

What is the market cap of Purple Biotech?

The market capitalisation of Purple Biotech is USD 4,16M

What is the 1 year trading range for Purple Biotech share price?

Purple Biotech has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Purple Biotech?

Purple Biotech reports financial results in USD

What is the latest annual profit for Purple Biotech?

The latest annual profit of Purple Biotech is USD -19,88M

What is the registered address of Purple Biotech?

The registered address for Purple Biotech is 4 OPPENHEIMER STREET, SCIENCE PARK, REHOVOT, CENTER, 7670104

What is the Purple Biotech website address?

The website address for Purple Biotech is www.purple-biotech.com

Which industry sector does Purple Biotech operate in?

Purple Biotech operates in the ARRANGE TRANS-FREIGHT, CARGO sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ABLVAble View Global Inc	US$ 1,73 (137,18%)	5,14M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	482,05M
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	622,67M
DWTXDogwood Therapeutics Inc	US$ 6,63 (49,66%)	25,92M
KZIAKazia Therapeutics Ltd	US$ 1,1899 (40,80%)	4,5M
ALBTAvalon GloboCare Corporation	US$ 6,96 (-36,15%)	577,55k
SCNXScienture Holdings Inc	US$ 1,55 (-35,68%)	1,59M
ACXPAcurx Pharmaceuticals Inc	US$ 0,4572 (-29,88%)	1,18M
RETOReTo Eco Solutions Inc	US$ 5,42 (-27,73%)	108,27k
OCTOEightco Holdings Inc	US$ 1,08 (-27,03%)	336,99k
BTOGBit Origin Ltd	US$ 0,6117 (118,46%)	618,03M
SUNESUNation Energy Inc	US$ 0,402999 (127,55%)	476,73M
NVDANVIDIA Corporation	US$ 112,69 (1,92%)	333,91M
ICONIcon Energy Corporation	US$ 0,169898 (17,17%)	140,23M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 10,675 (-0,70%)	140,05M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Purple Biotech Ltd (PPBT) Cours

Purple Biotech Ltd (PPBT)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Purple Biotech Ltd

PPBT Dernières nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Advances NT219 into Phase 2 Head and Neck Cancer Trial

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platform

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Purple Biotech Announces Closing of $2.8 Million Registered Direct Offering of American Depositary Shares

PPBT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR